Path Fertility secures $2 million NIH grant to develop and validate a semen-based epigenetic assay for NOA and cancer risk.

Agendia presented data on an AI pathology model that predicts breast cancer recurrence risk from routine biopsy slides.

Tempus xR RNA sequencing assay receives EU IVDR Class C certification, supporting continued clinical and biopharma access in ...

FDA grants bioMérieux dual clearance and CLIA waiver for the BIOFIRE SPOTFIRE Vaginitis Panel, a rapid 20-minute ...

Abbott’s WGS-based Oncodetect MRD test showed a 30% sensitivity improvement for post-surgical colorectal cancer recurrence.

Quest Diagnostics and Waters will expand at-home HPV screening in 2027, offering extended genotyping via the Onclarity ...

Illumina has introduced three early-access software capabilities on its BioInsight Platform designed to automate informatics ...

Guardant Health and partners will present 25 abstracts on liquid biopsy advances for cancer monitoring at ESMO 2026.

Gene by Gene will provide whole-genome sequencing for Children’s Mercy’s program, targeting nearly 100,000 pediatric genomes.

Hologic has agreed to acquire Reveal Genomics, adding the HER2DX assay to its breast cancer genomic testing portfolio, the ...

A study finds permissive lab screening thresholds double primary aldosteronism detection rates versus Endocrine Society ...

Hologic and Inpeco have partnered to connect Panther Systems with FlexLab X automation in Europe, aiming to improve ...